Intravenous Immunoglobulin (IVIG) and SCIG

Intravenous Immunoglobulin (IVIG) and SCIG

Intravenous immunoglobulin (IVIG) treatment is used in high doses for many immunologic and neurological disorders. It is also used in dermatology and rheumatology as replacement therapy. It is also used to treat certain blistering diseases. This treatment helps the body fight off infection and heals tissue damage.


One major advantage of SCIG treatment is that it carries a lower risk of serious systemic adverse events than IVIG. These adverse events include headache, fever, chills, nausea, and vomiting. Although rare, these reactions are troubling, especially for recently started IG therapy.


IVIG treatment is a form of immunoglobulin made from convalescent plasma. It has proven safe and effective in severe COVID-19 patients and has a reduced risk of disease progression. In addition, IVIG treatment improves survival. The treatment is currently in phase III clinical trials.


Hizentra, an immunoglobulin subcutaneous (20%) liquid, is a treatment for primary humoral immunodeficiency in adults and pediatric patients. It is indicated for primary or severe combined immunodeficiency. The drug is administered subcutaneously and is available as a single-use, tamper-evident vial. Hizentra contains 0.2 grams of protein per mL. It is a clear, pale yellow to the light brown solution. It should not be frozen or refrigerated.

Plasma exchange

A biological agent known as intravenous immunoglobulin is used to treat many antibody-mediated neurological disorders. It is derived from fractions of blood taken from thousands of donors. It is delivered intravenously in a drip that depends on the patient's weight and condition.

Myasthenic crises

Intravenous immunoglobulin, or IVIg, is a medication used to treat severe cases of myasthenia gravis. This treatment replaces lost antibodies and has been in use for decades. It is usually given in a single infusion or is delivered through multiple infusions over several days. However, some people do not respond to the medication. Therefore, patients should talk to their doctors about other treatments if this is not the best option.

Pemphigus vulgaris

Intravenous immunoglobulin (IVIG) treatment is an effective alternative for pemphigus vulgaris, a rare autoimmune disease affecting the skin and mucous membranes. This treatment is easily injected into the veins and is safe to use. It can help to cure pemphigus vulgaris and has been proven effective in several clinical trials.